As the pharmaceutical world continues to embrace innovation in patient care, novel treatments like TRYVIO in the United States and JERAYGO in Europe are reshaping the approach to chronic conditions such as nocturia. Developed by Ferring Pharmaceuticals, this desmopressin-based therapy addresses nocturia associated with nocturnal polyuria—a condition in which excessive nighttime urine...